Drug Trial Radar · NCT02576574
Avelumab in First-line NSCLC (JAVELIN Lung 100)
Last checked: Nov 20, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,214
Actual
Start
Oct 29, 2015
Primary completion
Dec 6, 2021
Study completion Jan 29, 2024
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Oct 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death ligand 1+ (PD-L1+) tumors.
Conditions
- First Line Non-Small Cell Lung Cancer
Interventions
AvelumabDrug
Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
PemetrexedDrug
Participants received Pemetrexed 500 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
PaclitaxelDrug
Participants received Paclitaxel 200 mg/m\^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
GemcitabineDrug
Participants received Gemcitabine 1250 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
GemcitabineDrug
Participants received Gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
CarboplatinDrug
Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL\*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
CisplatinDrug
Participants received Cisplatin 75 mg/m\^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
CarboplatinDrug
Carboplatin AUC 6 mg/mL\*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
Avelumab WeeklyDrug
Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)Time frame: Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
- Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Modified Full Analysis Set (mFAS)Time frame: Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
- Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)Time frame: Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
- Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)Time frame: Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Locations
349 sites in 42 countries. Site status is shown where the registry gives one.
Clearview Cancer Institute
Huntsville, Alabama
Arizona Center for Cancer Care
Surprise, Arizona
Sharp Memorial Hospital
San Diego, California
University Cancer Institute
Boynton Beach, Florida
South Georgia Medical Center
Valdosta, Georgia
Christus Cancer Treatment Center
Shreveport, Louisiana
Henry Ford Hospital
Detroit, Michigan
St. Vincent Frontier Cancer Center
Billings, Montana
Nevada Cancer Research Foundation
Las Vegas, Nevada
San Juan Oncology Associates
Farmington, New Mexico
Novant Health Oncology Specialists
Kernersville, North Carolina
Mercy Research
Oklahoma City, Oklahoma
Kaiser Permanente Northwest
Portland, Oregon
Lancaster Cancer Center
Lancaster, Pennsylvania
Cookeville Regional Medical Center
Cookeville, Tennessee
Thompson Cancer Survival Center
Knoxville, Tennessee
Coastal Bend Cancer Center
Corpus Christi, Texas
Oncology Consultants, P.A.
Houston, Texas
University of Vermont Medical Center
Burlington, Vermont
Northwest Medical Specialties, PLLC
Tacoma, Washington
Cheyenne Regional Medical Center
Cheyenne, Wyoming
Albury Wodonga Regional Cancer Centre
Albury, New South Wales, Australia
Coffs Harbour Health Campus
Coffs Harbour, New South Wales, Australia
St George Private Hospital
Kogarah, New South Wales, Australia
Lismore Base Hospital
Lismore, New South Wales, Australia
Orange Health Service
Orange, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Gallipoli Medical Research Foundation Ltd
Greenslopes, Queensland, Australia
Gold Coast University Hospital
Southport, Queensland, Australia
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Ballarat Base Hospital
Ballarat, Victoria, Australia
Bendigo Hospital
Bendigo, Victoria, Australia
South West Healthcare
Warrnambool, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
ZNA Middelheim
Antwerp, Belgium
A.Z. Klina
Brasschaat, Belgium
CHU Ambroise Paré
Mons, Belgium
INCA - Instituto Nacional de Câncer
Rio de Janeiro, Brazil
CRIO - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Showing 40 of 349 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.